Peter Kolchinsky Profile picture
Aug 4, 2020 15 tweets 4 min read Read on X
Here's an ALMOST GREAT explainer of why drugs cost more in the US than other countries. The one thing I would change is to reverse the logic of who subsidizes whom. Many think US subsidizes other countries' access to medicines. But in truth...
...other countries pitch in for cost of funding the drug industry to make drugs Americans need, reducing America's costs. We can wish for those countries to pay more, but it would be counter-productive to deny them access unless they pay more...
...b/c European countries are willing to deny their citizens access to new medicines & so they might just end up paying nothing at all. Trump's strategy of demanding US drug prices=EU drug prices, as with many things, is akin to threatening to cut off our nose to spite our face.
In this case, the nose is EU's contribution, however modest, to funding the drug industry's operating costs by buying branded drugs for somewhat lower prices than in the US (~20-40% lower).
And the face is the status quo, where Americans get new medicines and EU pays less than its fair share to also get them. Of course, what all this is about is achieving affordability for patients, which is a function of insurance.
Patients in EU can afford medicines they need not b/c those medicines are cheaper there but b/c EU patients pay little out of pocket. Consider... if a drug costs $20k, would cutting it to $12k make it affordable to most Americans w/o insurance or who have a $6000 deductible? No!
In fact, whether the drug costs $20k or $12k, to the patient w/American insurance it still costs $6k... the amount of the deductible. So for Americans to afford the medicines they need, they need insurance reform.
And if our government can negotiate with other countries to get them to pay more for branded drugs, that's great - it would either add more fuel to innovation or reduce America's share of paying for the innovation that Americans want. That's good either way.
In the meantime, the whole world can take heart in fact that drugs offer great value b/c they go generic, unlike anything else in healthcare. Hospitals don't... Doctors don't... which is what's driving up healthcare costs relentlessly.
But generic statins, for example, spare Americans and Europeans and people all over the world from having heart attacks, keeping them out of hospitals, averting pain, death, and wasteful spending on ER visits, hospital stays, and surgery.
Statins were expensive once, now not, & they keep saving us money on services. That's the major value proposition of drugs and almost NO ONE is talking about it. But Congress knows... at least the people who drafted the Hatch-Waxman Act and work on its amendments (like @JoeBiden)
The key drug/insurance reforms America should be focused on are achieving affordability by lowering out of pocket costs for patients and making sure America gets value for what it pays for branded drugs by making sure that all drugs go generic without undue delay.
And let's make sure that all countries pitch in for the cost of innovation at least what they are willing to, even if it's less than they can, because some help funding new medicines is better than none.
If you want America's government to appreciate the value of biomedical innovation and to implement the right reforms to make medicines affordable for all Americans, then we need more scientists in Congress, like chemist @ngoroff in NY. goroffforcongress.com/issues
I've written more on how to make medicines affordable and what prudent drug pricing reforms would look like here. If you don't read the book, there are many short articles on related issues. thegreatamericandrugdeal.com

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Peter Kolchinsky

Peter Kolchinsky Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @PeterKolchinsky

Mar 14, 2023
So let's get this right... @statnews elevates someone who would talk the US (as they have other countries) out of paying for a life-saving drug like Trikafta instead of recognizing the courage and intellect of someone like Gunnar Esiason @G17Esiason...
...who has #CF, considers himself fortunate to be able to get Trikafta in US thanks to insurance that hasn't yet totally succumbed to bad math, & advocates for the value of the lives of patients elsewhere, urging other countries not to fall for bad math.
realclearhealth.com/articles/2022/…
Should the staff at STAT recognize that they, like all of us, are or will someday be patients, they might not honor math that undervalues their lives and lives of their readers.
Read 4 tweets
Mar 12, 2023
Some say "urging calm" makes people panic more; stay quiet. I disagree.

The source of panic is uncertainty. People are afraid to talk about risks of a run on their bank in case they give everyone ideas. But everyone already is wondering about their bank. So let's talk.
SVB's failure is not some punishment for tech elite who can handle losing their money... because it's not about the elite and b/c depositors almost certainly won't be losing their money.
Though banks fail all the time affecting individuals and small businesses every year, they tend to be small regional banks. SVB is the largest since WaMu in 2008, and some of the most innovative companies in the US are simultaneously affected b/c that was SVB's specialty.
Read 24 tweets
Feb 24, 2023
One year since Russia attacked Ukraine, don’t take a moment of silence. Give real thought to year 2.

See how aid works in detail by reading @directrelief‘s report. See where money & medicines come from & where they go and how. Let that guide what you do directrelief.org/2023/02/ukrain…twitter.com/i/web/status/1…
Direct Relief is THE MAIN non-profit in the world capable of taking in, storing, and distributing donated medicines & other medical supplies to regions in need during peacetime, war, & catastrophe.
A year ago, some of us in biotech gave to DR to buy generators for hospitals. Several months ago, we donated to enable purchase of ambulances. All the while, @tevapharmeurope, @PerrigoCompany, @novartis, @pfizer, & many others have been donating literally tons of medicines.
Read 9 tweets
Feb 18, 2023
How much do you think ICER math (which Democratic Party often cites) would say US should spend on drugs/vaccines against smallpox in case of outbreak/pandemic?

(I estimate it spends ~$100m/year)

@statnews @SenateHELP @icer_review @IAmBiotech @PhRMA @SchaefferCenter @NPLB_org
Hint: ICER takes a very simplified approach to valuing a medicine that requires that someone be sick so they can be treated and get a measurable benefit in the present to score any value. If no one is sick, there is no benefit (no effectiveness).
So what happens when you divide even $1 by zero? That’s right. The equation breaks. Most people would say “but we are paying for those smallpox medicines/vaccines in case of an outbreak or pandemic”. That’s called risk reduction. It reflects that we value peace of mind.
Read 26 tweets
Feb 17, 2023
M&A is a necessary process of resorting products, cash, & people to where they are most highly valued. Whether the moment feels like sex or autophagy, it's disruptive to people who may wonder what their next job will be. We can help with that.
racap.com/the-right-job#…
There are tons of great jobs across our ecosystem. Many are at companies in the RA portfolio. When a company is going through M&A, at invitation of CEO & HR team, we presented to their team a Talent Briefing of many of the relevant jobs in the RA ecosystem.
And even Talent Briefings aside, if you are interested in learning more about those positions across our portfolio at anytime, here's the spot: open-positions.racap.com/?company=portf…
Read 4 tweets
Jan 13, 2023
Tension among insurance, innovator, & patients w/CF over access to life saving medicine is gutting. B/c Vertex was providing copay assistance, insurance plans stopped covering its drug. So Vertex cut back. Other innovators & their investors watching: what will patients do?
Here's how insurance and innovation are supposed to work together. Can't have most biomedical innovation w/ insurance, and insurance wouldn't be as valuable w/o treatments/cures to pay for. They are intertwined.
Insurance can ignore that value of medicine like Trikafta is much greater than seemingly high price society pays now. In the long run, this medicine will be generic and still saving lives. Vertex has transformed how humanity will think of CF forever. nopatientleftbehind.org/about/value-of…
Read 11 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(